- Home
- PFX vs PROK Comparison
PFX vs PROK Comparison
Compare PFX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFX
- PROK
- Stock Information
- Founded
- PFX 2010
- PROK 2015
- Country
- PFX United States
- PROK United States
- Employees
- PFX N/A
- PROK N/A
- Industry
- PFX Finance: Consumer Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFX Finance
- PROK Health Care
- Exchange
- PFX Nasdaq
- PROK Nasdaq
- Market Cap
- PFX 99.7M
- PROK 85.5M
- IPO Year
- PFX N/A
- PROK N/A
- Fundamental
- Price
- PFX $49.66
- PROK $4.74
- Analyst Decision
- PFX
- PROK Buy
- Analyst Count
- PFX 0
- PROK 4
- Target Price
- PFX N/A
- PROK $5.33
- AVG Volume (30 Days)
- PFX 1.9K
- PROK 33.1M
- Earning Date
- PFX 08-05-2025
- PROK 08-08-2025
- Dividend Yield
- PFX 2.90%
- PROK N/A
- EPS Growth
- PFX N/A
- PROK N/A
- EPS
- PFX 5.09
- PROK N/A
- Revenue
- PFX $24,036,577.00
- PROK $306,000.00
- Revenue This Year
- PFX $10.51
- PROK $54.34
- Revenue Next Year
- PFX N/A
- PROK N/A
- P/E Ratio
- PFX $9.71
- PROK N/A
- Revenue Growth
- PFX 15.02
- PROK N/A
- 52 Week Low
- PFX $44.56
- PROK $0.46
- 52 Week High
- PFX $57.40
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- PFX 53.59
- PROK 92.14
- Support Level
- PFX $49.00
- PROK $0.54
- Resistance Level
- PFX $51.50
- PROK $7.13
- Average True Range (ATR)
- PFX 0.42
- PROK 0.62
- MACD
- PFX -0.00
- PROK 0.47
- Stochastic Oscillator
- PFX 53.00
- PROK 68.59
About PFX PhenixFIN Corporation
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.